JP2020532585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532585A5 JP2020532585A5 JP2020533876A JP2020533876A JP2020532585A5 JP 2020532585 A5 JP2020532585 A5 JP 2020532585A5 JP 2020533876 A JP2020533876 A JP 2020533876A JP 2020533876 A JP2020533876 A JP 2020533876A JP 2020532585 A5 JP2020532585 A5 JP 2020532585A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- -1 thiono Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 C[n]1c2ncnc(*)c2nc1 Chemical compound C[n]1c2ncnc(*)c2nc1 0.000 description 5
- GSTFEDXYLJOASP-UHFFFAOYSA-N CC(C)[n]1c(C=NNC2=O)c2nc1 Chemical compound CC(C)[n]1c(C=NNC2=O)c2nc1 GSTFEDXYLJOASP-UHFFFAOYSA-N 0.000 description 1
- MMVXHMIFFAGTTP-UHFFFAOYSA-N CC(C)[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound CC(C)[n]1c(N=C(N)NC2=O)c2nc1 MMVXHMIFFAGTTP-UHFFFAOYSA-N 0.000 description 1
- WRXCXOUDSPTXNX-UHFFFAOYSA-N C[n]1c(ncnc2N)c2nc1 Chemical compound C[n]1c(ncnc2N)c2nc1 WRXCXOUDSPTXNX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552148P | 2017-08-30 | 2017-08-30 | |
| US62/552,148 | 2017-08-30 | ||
| US201862660565P | 2018-04-20 | 2018-04-20 | |
| US62/660,565 | 2018-04-20 | ||
| PCT/IB2018/056658 WO2019043634A2 (en) | 2017-08-30 | 2018-08-30 | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532585A JP2020532585A (ja) | 2020-11-12 |
| JP2020532585A5 true JP2020532585A5 (enExample) | 2021-10-07 |
| JP7311514B2 JP7311514B2 (ja) | 2023-07-19 |
Family
ID=65527221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533876A Active JP7311514B2 (ja) | 2017-08-30 | 2018-08-30 | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11773132B2 (enExample) |
| EP (1) | EP3692048A4 (enExample) |
| JP (1) | JP7311514B2 (enExample) |
| KR (1) | KR102782200B1 (enExample) |
| CN (1) | CN111263767B (enExample) |
| AU (1) | AU2018323053A1 (enExample) |
| BR (1) | BR112020004047A2 (enExample) |
| CA (1) | CA3073919A1 (enExample) |
| IL (1) | IL272928A (enExample) |
| MX (1) | MX2020002303A (enExample) |
| RU (1) | RU2020112502A (enExample) |
| SG (1) | SG11202001847WA (enExample) |
| TW (1) | TWI808092B (enExample) |
| WO (1) | WO2019043634A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| EP3585379A4 (en) | 2017-02-21 | 2020-12-02 | Board of Regents, The University of Texas System | CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR |
| CA3073919A1 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| KR20200130362A (ko) * | 2018-03-08 | 2020-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| BR112020024605A2 (pt) | 2018-06-01 | 2021-04-06 | Eisai R&D Management Co., Ltd. | Métodos para o tratamento de câncer de bexiga |
| CN112867727B (zh) * | 2018-10-12 | 2024-05-17 | 上海济煜医药科技有限公司 | 环二核苷酸类化合物及其应用 |
| WO2021013234A1 (en) * | 2019-07-25 | 2021-01-28 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| WO2021178818A2 (en) * | 2020-03-06 | 2021-09-10 | Beijing Xuanyi Pharmasciences Co., Ltd. | Therapeutic agents and conjugates thereof |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 | ||
| CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
| WO2022083584A1 (zh) * | 2020-10-20 | 2022-04-28 | 泰励生物科技（上海）有限公司 | 多功能环二核苷酸及其用途 |
| KR102466750B1 (ko) * | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| TW202233251A (zh) | 2020-11-09 | 2022-09-01 | 日商武田藥品工業股份有限公司 | 抗體藥物綴合物 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP2246363A1 (en) | 2002-11-15 | 2010-11-03 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US20060167241A1 (en) | 2003-07-15 | 2006-07-27 | Mitsui Chemicals, Inc. | Method for synthesizing cyclic bisdinucleoside |
| CA2533873A1 (en) * | 2003-07-28 | 2005-04-07 | David K.R. Karaolis | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
| AU2005222626B2 (en) | 2004-03-15 | 2010-05-20 | Karagen Pharmaceuticals, Inc. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| NZ596834A (en) | 2006-08-18 | 2013-06-28 | Novartis Ag | Prlr-specific antibody and uses thereof |
| CA2711938C (en) | 2008-01-15 | 2019-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
| DK3103476T3 (da) | 2009-03-02 | 2022-10-17 | Aduro Biotech Holdings Europe B V | Antistoffer mod en prolifererende inducerende ligand (april) |
| CU24094B1 (es) | 2010-08-20 | 2015-04-29 | Novartis Ag | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CA2908154C (en) | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| KR20160065858A (ko) | 2013-10-21 | 2016-06-09 | 드렉셀유니버시티 | 만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용 |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| KR20170015353A (ko) | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Ｓｔｉｎｇ의 조절제로서 사이클릭 디뉴클레오타이드 |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| CN107148424B (zh) | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| BR112018002757A8 (pt) | 2015-08-13 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio |
| AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| US20180369268A1 (en) | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| KR20250049441A (ko) | 2016-01-11 | 2025-04-11 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| EP3448393A1 (en) * | 2016-04-25 | 2019-03-06 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| US11001605B2 (en) * | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200113924A1 (en) | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| WO2018119274A1 (en) * | 2016-12-21 | 2018-06-28 | Fred Hutchinson Cancer Research Center | Scaffolds to treat solid tumor cells and escape variants |
| WO2018138684A1 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| CN110234403A (zh) * | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| CA3073919A1 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
| CN112867727B (zh) * | 2018-10-12 | 2024-05-17 | 上海济煜医药科技有限公司 | 环二核苷酸类化合物及其应用 |
-
2018
- 2018-08-30 CA CA3073919A patent/CA3073919A1/en not_active Abandoned
- 2018-08-30 SG SG11202001847WA patent/SG11202001847WA/en unknown
- 2018-08-30 WO PCT/IB2018/056658 patent/WO2019043634A2/en not_active Ceased
- 2018-08-30 AU AU2018323053A patent/AU2018323053A1/en not_active Abandoned
- 2018-08-30 EP EP18850228.0A patent/EP3692048A4/en active Pending
- 2018-08-30 JP JP2020533876A patent/JP7311514B2/ja active Active
- 2018-08-30 RU RU2020112502A patent/RU2020112502A/ru unknown
- 2018-08-30 BR BR112020004047-9A patent/BR112020004047A2/pt not_active IP Right Cessation
- 2018-08-30 KR KR1020207008457A patent/KR102782200B1/ko active Active
- 2018-08-30 TW TW107130419A patent/TWI808092B/zh active
- 2018-08-30 CN CN201880056293.1A patent/CN111263767B/zh active Active
- 2018-08-30 MX MX2020002303A patent/MX2020002303A/es unknown
- 2018-08-30 US US16/643,127 patent/US11773132B2/en active Active
-
2020
- 2020-02-26 IL IL272928A patent/IL272928A/en unknown